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Abstract 
Background: Vaccines against pandemic A/H1N1 influenza should provide 
protective immunity in children, because they are at greater risk of disease than 
adults. This study was conducted to identify the optimal dose of an MF59
®
-
adjuvanted, egg-derived, A/H1N1 influenza vaccine for young children. 
Methods: Children aged 6–11 months (N=144) and 12–35 months (N=186) received 
vaccine formulations containing either 3.75 μg antigen with half the standard dose of 
MF59, or 7.5 μg antigen with a standard dose MF59, or a non-adjuvanted formulation 
containing 15 g antigen (children 12-35 months only). Participants were given two 
primary vaccine doses three weeks apart, followed by one booster dose of MF59-
adjuvanted seasonal influenza vaccine one year later. Immunogenicity was assessed 
by haemagglutination inhibition and microneutralization assays. 
Results: All vaccine formulations were highly immunogenic and met all three 
European licensure criteria after two doses. MF59-adjuvanted vaccines met all 
licensure criteria after one dose in both age cohorts, while non-adjuvanted vaccine did 
not meet all criteria after one dose in children 12-35 months. A single booster dose 
was highly immunogenic and stable antibody persistence was observed in response to 
all vaccines. All vaccines were well tolerated.  
Conclusions: In this study a single dose of 3.75μg antigen with half the standard dose 
of MF59 was shown to be optimal, providing adequate levels of immediate and long-
term antibodies in paediatric subjects aged 6–35 months. These data demonstrated 
that MF59 adjuvant allowed for reduced antigen content and promoted significant 
long-term antibody persistence in children, with a satisfactory safety profile.  
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Abstract 
Background: Vaccines against pandemic A/H1N1 influenza should provide protective immunity in 
children, because they are at greater risk of disease than adults. This study was conducted to 
identify the optimal dose of an MF59
®
-adjuvanted, egg-derived, A/H1N1 influenza vaccine for 
young children. 
Methods: Children aged 6–11 months (N=144) and 12–35 months (N=186) received vaccine 
formulations containing either 3.75 μg antigen with half the standard dose of MF59, or 7.5 μg 
antigen with a standard dose MF59, or a non-adjuvanted formulation containing 15 g antigen 
(children 12-35 months only). Participants were given two primary vaccine doses three weeks apart, 
followed by one booster dose of MF59-adjuvanted seasonal influenza vaccine one year later. 
Immunogenicity was assessed by haemagglutination inhibition and microneutralization assays. 
Results: All vaccine formulations were highly immunogenic and met all three European licensure 
criteria after two doses. MF59-adjuvanted vaccines met all licensure criteria after one dose in both 
age cohorts, while non-adjuvanted vaccine did not meet all criteria after one dose in children 12-35 
months. A single booster dose was highly immunogenic and stable antibody persistence was 
observed in response to all vaccines. All vaccines were well tolerated.  
Conclusions: In this study a single dose of 3.75μg antigen with half the standard dose of MF59 was 
shown to be optimal, providing adequate levels of immediate and long-term antibodies in paediatric 
subjects aged 6–35 months. These data demonstrated that MF59 adjuvant allowed for reduced 
antigen content and promoted significant long-term antibody persistence in children, with a 
satisfactory safety profile.  
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Introduction 
 
The emergence of a novel strain of influenza A/H1N1 virus in the spring of 2009 led to the first 
pandemic of the 21
st
 century being declared by the World Health Organization.
1
  
Current evidence suggests that mass immunization is important for optimal disease control, with the 
vaccination of children essential in reducing infection rates within families and consequently 
throughout the wider population.
2-4
 Massive effort has been put into developing vaccines based on 
the A/California/7/2009 strain and disseminating them to large proportions of the population.  
The A/H1N1 pandemic strain disproportionately affected children and younger adults.
5
 Children 
may have been particularly affected because of close mixing at schools allowing for increased 
transmission,
6
 and because of the lack of previous exposure to this viral strain. Thus, it was 
important that any candidate vaccine was effective in all age groups, including children.  
 
The oil-in-water adjuvant MF59
®
 (Novartis Vaccines and Diagnostics) has been shown to be 
effective in pandemic A/H1N1 vaccines for adults and children, and has an acceptable safety 
profile.
7-11
 Adjuvants help to increase the immune response to vaccines, achieving higher antibody 
titres that lead to protection with less amount of antigen.
12-15
 The ability to generate adequate 
immunity in the individual while using as little antigen as possible is crucially important during a 
pandemic, when the global capacity for vaccine production is stretched to the limit. 
 
The MF59-adjuvanted, egg-based, monovalent vaccine, Focetria
®
 (Novartis Vaccines and 
Diagnostics), is based on the A/H1N1 California/7/2009 strain, and was approved for use by the 
European Medicines Agency with an antigen content of 7.5 μg per dose.16 A previous clinical trial 
demonstrated a single dose of this vaccine was sufficient to meet the European licensure criteria for 
pandemic influenza vaccines in both adults and elderly.
17
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The aim of this study was to identify priming antigen and adjuvant doses resulting in optimal 
antibody levels shortly after primary immunization and one-year booster immunizations in children 
aged 6–35 months. In addition, long-term antibody persistence and vaccine safety were assessed up 
to 18 months after vaccination. 
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Materials and Methods 
 
This multinational, single-blind, randomized, Phase III, dose-ranging study was conducted across 
eleven sites in Germany, two sites in Belgium, one site in The Netherlands, two sites in The 
Dominican Republic, and two sites in Chile between September 2009 and July 2011. One German 
site was excluded from analyses due to noncompliance with the protocol requirements for safety 
reporting for a different study. The trial was performed in accordance with Good Clinical Practice 
guidelines and the Declaration of Helsinki. The protocol was reviewed and approved by the 
Institutional Review Board or Ethics Committee of each participating institution. Written informed 
consent was obtained from the parent or legal guardian of all subjects before their enrolment in the 
study. This clinical trial was registered at ClinicalTrials.gov: NCT00971542. 
 
Subjects 
A total of 684 healthy children 6 months to 17 years of age entered this study, of which 330 
children were included in one of the younger age cohorts (6-11 months; 12-35 months) covered in 
this paper. The results of the older age cohorts (3-8 years; 9-17 years) will be reported separately.  
Exclusion criteria included a history of, or ongoing serious illness; a history of anaphylaxis; 
hypersensitivity or previous adverse reactions to vaccination or to influenza viral proteins, eggs, or 
chicken protein; receipt of any adjuvanted influenza vaccine within three months prior to 
enrolment; influenza disease within three months prior to enrolment; receipt of any investigational 
agent within four months prior to enrolment; receipt of any other vaccine within four months prior 
to enrolment, with the exception of non-adjuvanted seasonal influenza vaccine one week before and 
after study vaccinations; an impaired immune system; and the receipt of blood or plasma derivatives 
within twelve weeks prior to study enrolment. 
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Study procedures 
Subjects were divided into 6–11 and 12–35 month-old cohorts. Subjects in the 6–11 months age 
group were randomized in a 1:1 ratio to receive vaccine containing either 7.5 g antigen with a full 
dose of MF59 (7.5-Full MF59) or 3.75 g antigen with half a dose of MF59 (3.75-Half MF59). 
Subjects in the 12–35 months age group were randomized in a 2:2:1 ratio to receive 3.75-Half 
MF59 vaccine, 7.5-Full MF59 vaccine, and a non-adjuvanted formulation containing 15 g antigen 
(15-No MF59), respectively. When the study was designed at the very beginning of the pandemic, it 
was thought based on previous A/H5N1 data, that the immunogenicity of the nonadjuvanted 
formulation would be suboptimal.
18, 19
 Therefore, to minimize the number of subjects that were 
supposed to receive this formulation, it was limited to the 12-35 months age cohort (and the 3-8 
years age cohort, results reported elsewhere).  
Subjects were randomly assigned to study groups using a system of sealed envelopes. The identity 
of the study vaccine was not revealed to the subject or their parent/legal guardian. All subjects 
received two doses of vaccine given three weeks apart. A booster dose of MF59-adjuvanted, 
seasonal, trivalent influenza vaccine (MF59-TIV) was administered one year after primary 
immunization. In addition, subjects who had never previously received seasonal vaccine were given 
a second dose of MF59-TIV three weeks later to complete the seasonal immunization course 
according to WHO recommendations.
20
 Therefore, subjects received one dose on Day 1, a second 
dose on Day 22 (primary doses), a third dose on Day 366 (booster), and, where applicable, a fourth 
dose on Day 387 (Figure 1). Vaccines were administered either in the deltoid muscle of the non-
dominant arm (subjects 24 months-old) or in the anterolateral thigh muscle (subjects <24 months-
old). Blood samples (5 mL per sample) were collected for immunogenicity analyses on Day 1 
(baseline, pre-vaccination), Day 22 (three weeks after first primary dose, before the second primary 
dose), Day 43 (three weeks after second primary dose), Day 366 (one year after primary 
immunization, before the booster), and Day 387 (three weeks after booster vaccination). The 
immunogenicity of the second seasonal immunization was not investigated. Safety data were 
collected up to 18 months after study entry.  
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Vaccines 
The investigational, egg-derived, monovalent, MF59-adjuvanted, pandemic vaccine, Focetria
®
 
(Novartis Vaccines and Diagnostics), contained haemagglutinin and neuraminidase surface antigens 
derived from the A/H1N1/California/7/2009 influenza strain. The vaccine seed A/H1N1 virus was 
prepared from the reassortant virus, NYMC X-179A (New York Medical College, New York, 
USA), generated from the A/California/7/2009 strain, as recommended by the World Health 
Organization.
21
 A full/standard dose of MF59, as used in the commercial seasonal influenza 
vaccine, Fluad
®
 (Novartis Vaccines and Diagnostics), contains 9.75 mg squalene, 1.18 mg 
polysorbate 80, 1.18 mg sorbitan trioleate, 0.66 mg sodium citrate dehydrate, and 0.04 mg citric 
acid monohydrate. The booster dose of the seasonal, MF59-adjuvanted, trivalent influenza vaccine 
(MF59-TIV), Fluad, contained a standard dose of MF59, and 15 g of each of the World Health 
Organization reference strains recommended for the 2010/11 influenza season: A/California/7/2009 
(H1N1); A/Perth/16/2009 (H3N2); and B/Brisbane/60/2008. Thus, the A/H1N1 antigen strain 
contained in both priming and booster vaccines were identical. Vaccines were supplied in pre-filled 
syringes. Single doses of 7.5-Full MF59 and 15-No MF59 vaccines were administered in a volume 
of 0.5 mL. A single dose of the 3.75-Half MF59 formulation was administered in a volume of 0.25 
mL. Single doses of seasonal vaccine were administered in volumes of 0.5 mL or 0.25 mL for 
subjects aged ≥36 months and <36 months at the time of booster administration, respectively. 
 
Immunogenicity assessments 
Blood samples were obtained by venipuncture and centrifuged at 1500 g for 10 minutes; sera were 
stored at a temperature of -18C or below and shipped to the Novartis Vaccines Clinical Serology 
Laboratory in Marburg, Germany, where antibody responses were assessed by haemagglutination 
(HI) and microneutralization (MN) assays. The HI assay was based on the method of Stephenson 
and colleagues;
22
 HI titre was expressed as the reciprocal of the highest dilution at which 
haemagglutination was totally inhibited. MN assays were performed according to a method 
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previously described by Nicholson and colleagues, serial dilutions of serum started at 1:20; the 
reciprocals of two-fold dilutions that achieved ≥ 50% neutralization of viral growth were considered 
a positive result.
23
 Titers were reported in terms of Geometric Mean Titers (GMT). Geometric Mean 
Ration (GMR) were calculated as GMT Day 22/GMT Day 1, GMT Day 43/GMT Day 1, GMT Day 
366/GMT Day 1 and GMT Day 387/GMT Day 366. In addition, HI GMT titers greater or equal 
than 1: 40 were assessed. Seroconversion, as assessed by HI assay, was defined as a negative pre-
vaccination antibody titre of < 1:10 to a positive post-vaccination titre of ≥ 1:40, or a minimum 
four-fold increase where pre-vaccination titres were ≥ 1:10. HI titres below the detection limit of 
1:10 were arbitrarily assigned to half that limit (1:5) for the purpose of analysis. The HI titer of 
1:40, which has been determined as an immunologic correlate corresponding to a 50% reduction in 
the risk of contracting influenza, is based on studies in adults and may not be generalizable to 
children. Indeed, a recent study in a large pediatric population indicated that the conventional HI 
titer of 1:40 was only associated with 22% protection.
24
 Therefore, percentages of subjects with HI 
titers ≥ 1:330 were also calculated, as this cut-off titer has been shown to predict an 80% clinical 
protective level in young children. Homologous HI and MN assays were performed using the 
vaccine antigen strain A/California/7/2009 (H1N1). 
 
Safety assessment 
Subjects were observed for 30 minutes after receipt of each vaccine dose to monitor for immediate 
adverse reactions. The frequency and severity of solicited local and systemic reactions occurring 
within one week of each vaccination were recorded on diary cards and summarized according to the 
Brighton collaboration case definition.
25
 Solicited local reactions were ecchymosis, erythema, 
induration, swelling, (categorized as none, 1≤ 10 mm, 11 to ≤25 mm, 26 to ≤50 mm, 51 to ≤100 
mm and >100 mm [severe local reactions]) and tenderness (categorized as none, minor light 
reaction to touch, cried or protested to touch, cried when injected limb was moved [severe]).  
Solicited systemic reactions were sleepiness, diarrhoea, vomiting, irritability, altered eating habits, 
shivering, unusual crying, and fever (≥ 38C). A high, grade 3 fever was defined as an axillary body 
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temperature of ≥ 40C. Solicited systemic reactions were collected as present/not present. In 
addition, use of analgesic/antipyretic was collected as measure of reactogenicity. All unsolicited 
adverse events (AE) were recorded for three weeks after each vaccination. The onset of new chronic 
diseases, serious adverse events (SAEs), and AEs leading to withdrawal were recorded throughout 
the entire study period (Day 1–546). A physician rated AEs as mild, moderate, or severe if resulting 
in no limitation of, some limitation of, or inability to perform normal daily activities, respectively. 
 
Statistical analyses 
Sample sizes were chosen to meet or exceed the minimum requirements of the European guidelines 
for influenza vaccine clinical trials. No formal statistical hypothesis was tested, immunogenicity 
endpoints being based on HI licensure criteria established by the EU Committee for Medicinal 
Products for Human Use (CHMP).
26
 There are currently no pre-defined CHMP criteria for children, 
therefore, the following adult licensure criteria applied: the number of subjects achieving 
seroconversion or significant increase (defined as HI ≥ 1:40 for subjects with a pre-vaccination HI 
titer <1:10; a minimum 4-fold increase HI titer for subjects with a pre-vaccination HI titer ≥1:10) 
should be > 40%; geometric mean ratios (GMRs) should be > 2.5; and the proportion of subjects 
achieving an HI titre ≥ 1:40 should be > 70%. 
Percentages of subjects with HI titers ≥ 1:330 were also calculated.24 Immunogenicity data 
reflecting the above endpoints as well as the corresponding two-sided 95% confidence intervals 
(CIs) were calculated for each vaccine group and age cohort using two-way analysis of variance 
(ANOVA) with factors for vaccine group and center. Safety data were evaluated descriptively and 
expressed as the proportion and number of subjects with AEs in each group. Immunogenicity 
analyses were run on the per-protocol (PP) set, which consisted of subjects who received all the 
relevant doses of vaccine correctly, provided evaluable serum sample at the relevant time points, 
and had no major protocol violations. Safety was analyzed for all subjects exposed to at least one 
study vaccination and provided safety data. All statistical analyses were performed by employees of 
Novartis Vaccines and Diagnostics using SAS 9.1
®
 software. 
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Results 
After the removal of one study site, 330 subjects were included in the two age cohorts (6-11 months 
and 12-35 months) covered in this paper.  In this study, 64-78% across groups completed the study 
protocol (Figure 1). An average of 93% and 72% of subjects across study groups completed the 
primary immunization schedule (Day 43) and received the booster dose (Day 366), respectively. A 
second dose of seasonal vaccine at Day 387 was administered to about 47% of subjects across 
vaccine groups in both age cohorts. 
Demographic and other baseline population characteristics are shown in Table 1. The majority of 
children were of Hispanic ethnic origin. In the youngest age cohort 6-11 months, 144 subjects were 
enrolled from 10 study sites, i.e. 4 in Germany (n=13), 2 in Belgium (n=17), 2 in Chilli (n=70) and 
2 sites in the Dominican Republic (n=44). In the age cohort 12-35 months, a total of 186 subjects 
were enrolled from 8 study sites, i.e. 2 in Germany (n=10), 1 in the Netherlands (n=4), 2 in Belgium 
(n=69), 2 in Chile (n=81) and 1 site in the Dominican Republic (n=22). Mean age of the subjects 
was 8.5 months and 24.2 months in cohorts 6-11 months and 12-35 months, respectively 
 
Immunogenicity 
Immunogenicity analyses were performed on the PP data set, which included 68-76% of subjects 
across groups after the primary vaccination schedule (Day 43), 49-53% of subjects for persistence 
analyses (Day 366), and 32-55% of subjects for post-booster analyses (Day 387).   
HI assay GMTs were low at baseline, with only 18–26% of subjects displaying HI titres of ≥ 1:40 
(Table 2). In the 6–11 months cohort, 7.5-Full MF59 vaccine induced greater GMTs than the 3.75-
Half MF59 formulation three weeks after both first and second doses (Figure 2A). One dose of 
either MF59-adjuvanted vaccine was sufficient to meet the CHMP criterion for GMR (Table 2). In 
the 12–35 months cohort, the 7.5-Full MF59 vaccine induced greater GMTs than the 3.75-Half 
MF59 formulation after first and second doses (Figure 2B). GMTs were greater in response to both 
MF59-adjuvanted vaccines compared with the 15 g non-adjuvanted formulation (Figure 2B). All 
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three vaccine formulations met the licensure criterion for GMRs as early as 3 weeks after the first 
vaccination (Table 2). Subjects in the 6–11 months cohort demonstrated high HI seroconversion 
rates for both formulations after the first and second vaccinations (91–98%); the same was true in 
subjects in the 12–35 months cohort who received adjuvanted formulations (97–100%; Table 2). 
Seroconversion rates were lower in subjects who received the 15-No MF59 formulation (52% on 
Day 22 and 74% on Day 43) than those who received adjuvanted formulations. For both age 
cohorts, seroconversion rates for all vaccines were above the CHMP licensure criterion of > 40% 
after both the first and second vaccinations. Rates of subjects with HI titers ≥ 1:40 were high after 
first and second doses in response to both adjuvanted formulations in both age cohorts, ranging 
from 91% to 100% (Figure 3A and B), exceeding the CHMP criterion of > 70%. Rates of subjects 
with HI titers ≥ 1:40 in the 15-No MF59 vaccination group of the 12–35 months cohort failed to 
meet licensure criterion after the first dose (52%); a second dose was required for this criterion to be 
achieved (81%) (Figure 3B). Analyses by MN assay supported HI data (Figure 2C and D, Table 
3). 
Long-term antibody persistence was demonstrated in subjects receiving MF59-adjuvanted vaccines; 
95–100% of subjects across age groups achieved HI titers ≥ 1:40 one year after immunization, 
which is considerably higher than in those receiving the non-adjuvanted formulation (62%) (Figure  
3A and B). Antibody titres were significantly higher after booster vaccination compared with 
GMTs after priming doses (Figure 2). The licensure criteria for GMR and seroconversion were met 
by all priming groups following booster vaccination in both age cohorts (Table 2) and all subjects 
achieved HI titers ≥ 1:40 in all vaccine groups in both age cohorts, regardless of priming 
formulations.. Analyses by MN assay supported HI data (Figure 2C and D, Table 3). 
Percentages of subjects with HI titers ≥ 1:330 are reported in Table 4. In the 6–11 months cohort, 
35% (3.75-Half MF59), 39% (7.5-Full MF59) and 82% (3.75-Half MF59), 100% (7.5-Full MF59) 
of subjects achieved HI titers ≥ 1:330 after the first and second primary doses, respectively, and all 
subjects in both vaccine groups had HI titers ≥ 1:330 after the booster vaccination.  
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In children 12-35 months of age receiving adjuvanted formulations, percentages of subjects 
achieving HI titers ≥ 1:330 were higher compared with subjects receiving the nonadjuvanted 
formulation. HI titers ≥ 1:330 were achieved in 37% (3.75-Half MF59), 47% (7.5 Full MF59), 23% 
(15-No MF59), and 85% (3.75-Half MF59), 91% (7.5-Full MF59), 39% (15-No MF59) after the 
first and second primary doses, respectively and in 100% (both adjuvanted formulations) and 91% 
(15-No MF59) of subjects after the booster dose.  
Safety and tolerability 
All subjects were exposed to at least one study vaccination and contributed to the safety analyses. 
In the 6–11 months cohort, the percentage of subjects with solicited local reactions were similar 
between first and second primary doses, and between the two adjuvanted formulations (Table 5).  
The most frequently reported local reactions after primary immunizations were erythema (15–25% 
of subjects) and tenderness (14–25%). There were no cases of severe local reactions after primary 
vaccinations. Local reactions were generally more frequent after the booster dose than the primary 
doses. Tenderness was the most frequently reported local reaction after the booster (34–39%) and 
second (23–30%) seasonal dose, followed by erythema (28–31% and 22–30%, respectively). Severe 
reactions were reported in up to 8% and 6% across groups after booster dose and second seasonal 
dose, respectively, with tenderness as the most frequently reported severe local reaction. The 
incidence of solicited systemic reactions was generally lower after the second primary vaccination 
compared with the first primary vaccination in the 6–11 months cohort, no substantial differences 
were observed between the vaccine groups. The incidence of systemic reactions after the booster 
was similar to that after the second primary vaccination. The incidence of local and systemic 
reactions tended to be lower after the second seasonal vaccination compared to the booster (Table 
5).  
In the 12–35 months cohort (Table 6), solicited local reactions were less frequent in the non-
adjuvanted formulation compared with the adjuvanted formulations and occurred at a similar rate 
after the first and second primary doses. 
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Tenderness was the most frequently reported local reaction after the primary immunizations (22–
35%), increasing in frequency after the booster (34–48%), but decreasing in frequency after the 
second seasonal dose (15–29%). Other local reactions occurred at a similar rate after the primary 
and booster vaccinations, but tended to occur at a lower rate after the second seasonal vaccination. 
After primary immunizations, severe tenderness was reported in 1-3% of subjects across adjuvanted 
groups, and severe induration and erythema occurred in 1% of subjects receiving 7.5-full MF59. 
Following booster and second seasonal dose, severe tenderness was reported in up to 5% of subjects 
across adjuvanted formulations. Systemic reactions tended to be similar between the vaccine 
formulations after the primary immunizations in the 12–35 months cohort.  
There were three reports of fever ≥ 40C: one 
 
Between study Days 1 and 43, 
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After the booster vaccination, the most frequently reported unsolicited AEs were nasopharyngitis 
(12–13%), and diarrhoea (2–6%) in the 6–11 months cohort, and nasopharyngitis (6–9%) and 
conjunctivitis (0–5%) in the 12-15 months cohort. Nasopharyngitis was also the most frequently 
reported AE after the second dose of the seasonal MF59 vaccine in both the 6–11 months (15%) 
and 12–35 months (12%) cohorts.  
One 6–11 month-old subject in the 3.75-Half MF59 group experienced one SAE, and one 12–35 
month-old subject in the 3.75-Half MF59 group experienced two SAEs between booster 
administration and the end of the study (Day 366–546). No SAEs were related to either the booster 
or the second seasonal vaccination. There was one new onset of chronic disease in 6-11 month 
(asthmatic crisis) and 12-35 month (allergic rhinitis) age cohorts, and one AE leading to premature 
study withdrawal in a 6-11 month-old subject (food allergy), none of which related to study 
vaccination between booster administration and the end of the study.   
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Discussion 
 
All the investigational vaccines used in this study were shown to be highly immunogenic and well 
tolerated in children from 6 to 35 months of age. A single dose of either the 3.75-Half MF59 or 7.5-
Full MF59 vaccines was sufficient to meet all three European licensure criteria for influenza 
vaccines in both age cohorts; two doses of the non-adjuvanted vaccine were required to achieve 
similar results in subjects aged 12-35 months. The ability of MF59 to allow for reduced antigen 
content would potentially ensure a higher coverage during a pandemic outbreak, which is an 
important public health issue to consider in periods of heightened demand. 
The findings of this study are supported by similar trials. A cell culture-derived, MF59-adjuvanted 
A/H1N1 vaccine has been demonstrated to provide adequate levels of antibodies after a single dose 
in British adults 
9
 and Japanese adults and children.
12, 27
 Adults were found to require one 3.75-Half 
MF59 vaccine dose, while a single 7.5-Full MF59 dose was optimal for children in the Japanese 
study.
27
  Also, a single dose of 3.75-Half MF59 and 7.5-Full MF59 fulfilled the licensure criteria 
for adult and elderly subjects 3 months after seasonal vaccination, or concomitantly with seasonal 
vaccination, without compromising the tolerability or immunogenicity of either vaccine.
11
 
A trial of A/H1N1 vaccine was conducted in Costa Rican children to compare an MF59-adjuvanted 
formulation containing 7.5 g of A/California/7/2009 antigen with 15 g and 30 g non-adjuvanted 
vaccines.
7
 All three vaccines met the US Center for Biologics Evaluation and Research (CBER) and 
CHMP licensure criteria after one dose in subjects aged 9–17 years; only the MF59-adjuvanted 
formulation met these criteria after one dose in younger subjects of 3 to 8 years. 
Paediatric and adult clinical trials using the oil-in-water adjuvant AS03
®
-adjuvanted 
(GlaxoSmithKline Biologicals, Wavre, Belgium) provided further evidence of the benefits of 
adjuvanted A/H1N1 vaccines. 
28-31
 
It has recently been demonstrated that the conventional titer of 1:40 correlate may not be 
appropriate in a pediatric population.
24
 A titer of 1:40 was only associated with 22% protection, 
whereas titers of 1:110 or 1:330 could predict a 50% or an 80% of clinical protective level.
24
 Our 
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results demonstrate that in children receiving MF59 adjuvanted formulations, a high proportion 
reached the stringent HI cut-off titer ≥ 1:330 postvaccination, i.e. 82-100% and 100% after primary 
and booster doses respectively, as compared with 39% in children receiving the non-adjuvanted 
vaccine. The seasonal MF59 vaccine was able to boost the immune responses also in the group 
primed with the nonadjuvanted formulation: indeed, 91% of subjects primed with the non-
adjuvanted vaccine reached the HI cut-off titer ≥ 1:330.  These findings give strong support for the 
use of MF59 adjuvanted vaccines in the pediatric population.  
In the present study, significant antibody persistence was observed in response to the MF59-
adjuvated vaccine formulations, with HI titers ≥ 1:40 detected in 95–100% of subjects one year 
after immunization. The ability of MF59 to promote long-term antibody persistence has also been 
demonstrated in previous studies.
32, 33
 All subjects in the current study received two priming doses; 
as such, further investigations are required to confirm that long-term antibody persistence and 
response to booster vaccination is not negatively affected by a one-dose priming schedule. The 
production of cross-reactive antibodies able to provide heterologous immunity was not analysed 
during this study. However, the ability of MF59 to promote the production of cross-reactive 
antibodies is well documented.
32, 34-36 
The overall safety and tolerability were as expected in this age group and were in line with previous 
studies using MF59-adjuvanted vaccines in young children.
15, 27, 37, 38
 Solicited local reactions were 
more common in adjuvanted formulations compared with nonadjuvanted vaccine, but there were no 
MF59-related increase in the frequency of solicited systemic reactions or unsolicited adverse 
events. This study demonstrated an acceptable safety profile for the adjuvanted vaccine over an 18-
month period; although subjects were repeatedly vaccinated with up to four doses of MF59-
adjuvanted vaccine, no vaccine-related SAEs were reported during the study period. 
In conclusion, a single dose of 3.75μg antigen together with half the standard dose of MF59 was 
identified as optimal, provided adequate levels of immediate and long-term antibodies and an 
acceptable safety profile in children 6-35 months of age. These data support the suitability of 
MF59-adjuvanted vaccines for pandemic immunization in the paediatric population. 
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Figure legends 
 
Figure 1: Design of clinical trial and subject disposition. 
 
Figure 2: GMTs by HI (A and B) and MN (C and D) assay at baseline (Day 1), three weeks after 
first (Day 22) and second (Day 43) priming doses, and pre- and post-booster vaccination in children 
aged 6–11 months- (A and C) and 12–35 months old (B and D). 
 
Figure 3: Percentages (95% CI) of subjects aged 6–11 months (A) and 12–35 months (B) achieving 
HI titer ≥ 1:40 after primary and booster immunizations. Broken line represents the CHMP 
licensure criteria. 
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Introduction 
 
The emergence of a novel strain of influenza A/H1N1 virus in the spring of 2009 led to the first 
pandemic of the 21
st
 century being declared by the World Health Organization.
1
 Mass immunization 
is currently the most effective way to prevent disease in the individual and limit human-to-human 
viral transmission. Massive effort has been put into developing vaccines based on the 
A/California/7/2009 strain and disseminating them to large proportions of the population. The 
A/H1N1 pandemic strain disproportionately affected children and younger adults.
2
 Children may 
have been particularly affected because of close mixing at schools allowing for increased 
transmission,
3
 and because of the lack of previous exposure to this viral strain. Thus, it was 
important that any candidate vaccine was effective in all age groups, including children.  
 
The oil-in-water adjuvant MF59
®
 (Novartis Vaccines and Diagnostics) has been shown to be 
effective in pandemic A/H1N1 vaccines for adults and children, and has an acceptable safety 
profile.
4-7
 Adjuvants help to increase the immune response to vaccines, achieving higher antibody 
titres that lead to protection with less amount of antigen. The ability to generate adequate immunity 
in the individual while using as little antigen as possible is crucially important during a pandemic, 
when the global capacity for vaccine production is stretched to the limit. 
 
The MF59-adjuvanted, egg-based, monovalent vaccine, Focetria
®
 (Novartis Vaccines and 
Diagnostics), is based on the A/H1N1 California/7/2009 strain, and was approved for use by the 
European Medicines Agency with an antigen content of 7.5 μg per dose.8 A previous clinical trial 
demonstrated a single dose of this vaccine was sufficient to meet the European licensure criteria for 
pandemic influenza vaccines in both adults and elderly.
9
 In the interest of conserving antigen and 
adjuvant, it is essential to investigate whether a single dose of MF59-adjuvanted A/H1N1 vaccine 
of reduced antigen content can provide adequate levels of antibodies in young children. 
 
Manuscript
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The aim of this study was to identify priming antigen and adjuvant doses resulting in optimal 
antibody levels shortly after primary immunization and one-year booster immunizations in children 
aged 6–35 months. In addition, long-term antibody persistence and vaccine safety were assessed up 
to 18 months after vaccination. 
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Materials and Methods 
 
This multinational, single-blind, randomized, Phase III, dose-ranging study was conducted across 
eleven sites in Germany, two sites in Belgium, one site in The Netherlands, two sites in The 
Dominican Republic, and two sites in Chile between September 2009 and July 2011. One German 
site was excluded from analyses due to noncompliance with the protocol requirements for safety 
reporting for a different study. The trial was performed in accordance with Good Clinical Practice 
guidelines and the Declaration of Helsinki. The protocol was reviewed and approved by the 
Institutional Review Board or Ethics Committee of each participating institution. Written informed 
consent was obtained from the parent or legal guardian of all subjects before their enrolment in the 
study. This clinical trial was registered at ClinicalTrials.gov: NCT00971542. 
 
Subjects 
A total of 684 healthy children 6 months to 17 years of age entered this study, of which 330 
children were included in one of the younger age cohorts (6-11 months; 12-35 months) covered in 
this paper. The results of the older age cohorts (3-8 years; 9-17 years) will be reported separately.  
Exclusion criteria included a history of, or ongoing serious illness; a history of anaphylaxis; 
hypersensitivity or previous adverse reactions to vaccination or to influenza viral proteins, eggs, or 
chicken protein; receipt of any adjuvanted influenza vaccine within three months prior to 
enrolment; influenza disease within three months prior to enrolment; receipt of any investigational 
agent within four months prior to enrolment; receipt of any other vaccine within four months prior 
to enrolment, with the exception of non-adjuvanted seasonal influenza vaccine one week before and 
after study vaccinations; an impaired immune system; and the receipt of blood or plasma derivatives 
within twelve weeks prior to study enrolment. 
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Study procedures 
Subjects were divided into 6–11 and 12–35 month-old cohorts. Subjects in the 6–11 months age 
group were randomized in a 1:1 ratio to receive vaccine containing either 7.5 g antigen with a full 
dose of MF59 (7.5-Full MF59) or 3.75 g antigen with half a dose of MF59 (3.75-Half MF59). 
Subjects in the 12–35 months age group were randomized in a 2:2:1 ratio to receive 3.75-Half 
MF59 vaccine, 7.5-Full MF59 vaccine, and a non-adjuvanted formulation containing 15 g antigen 
(15-No MF59), respectively. Subjects were randomly assigned to study groups using a system of 
sealed envelopes. The identity of the study vaccine was not revealed to the subject or their 
parent/legal guardian. All subjects received two doses of vaccine given three weeks apart. A booster 
dose of MF59-adjuvanted, seasonal, trivalent influenza vaccine (MF59-TIV) was administered one 
year after primary immunization. In addition, subjects who had never previously received seasonal 
vaccine were given a second dose of MF59-TIV three weeks later to complete the seasonal 
immunization course according to WHO recommendations.
10
 Therefore, subjects received one dose 
on Day 1, a second dose on Day 22 (primary doses), a third dose on Day 366 (booster), and, where 
applicable, a fourth dose on Day 387 (Figure 1). Vaccines were administered either in the deltoid 
muscle of the non-dominant arm (subjects 24 months-old) or in the anterolateral thigh muscle 
(subjects <24 months-old). Blood samples (5 mL per sample) were collected for immunogenicity 
analyses on Day 1 (baseline, pre-vaccination), Day 22 (three weeks after first primary dose, before 
the second primary dose), Day 43 (three weeks after second primary dose), Day 366 (one year after 
primary immunization, before the booster), and Day 387 (three weeks after booster vaccination). 
The immunogenicity of the second seasonal immunization was not investigated. Safety data were 
collected up to 18 months after study entry.  
 
Vaccines 
The investigational, egg-derived, monovalent, MF59-adjuvanted, pandemic vaccine, Focetria
®
 
(Novartis Vaccines and Diagnostics), contained haemagglutinin and neuraminidase surface antigens 
derived from the A/H1N1/California/7/2009 influenza strain. The vaccine seed A/H1N1 virus was 
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prepared from the reassortant virus, NYMC X-179A (New York Medical College, New York, 
USA), generated from the A/California/7/2009 strain, as recommended by the World Health 
Organization.
11
 A full/standard dose of MF59, as used in the commercial seasonal influenza 
vaccine, Fluad
®
 (Novartis Vaccines and Diagnostics), contains 9.75 mg squalene, 1.18 mg 
polysorbate 80, 1.18 mg sorbitan trioleate, 0.66 mg sodium citrate dehydrate, and 0.04 mg citric 
acid monohydrate. The booster dose of the seasonal, MF59-adjuvanted, trivalent influenza vaccine 
(MF59-TIV), Fluad, contained a standard dose of MF59, and 15 g of each of the World Health 
Organization reference strains recommended for the 2010/11 influenza season: A/California/7/2009 
(H1N1); A/Perth/16/2009 (H3N2); and B/Brisbane/60/2008. Thus, the A/H1N1 antigen strain 
contained in both priming and booster vaccines were identical. Vaccines were supplied in pre-filled 
syringes. Single doses of 7.5-Full MF59 and 15-No MF59 vaccines were administered in a volume 
of 0.5 mL. A single dose of the 3.75-Half MF59 formulation was administered in a volume of 0.25 
mL. Single doses of seasonal vaccine were administered in volumes of 0.5 mL or 0.25 mL for 
subjects aged ≥36 months and <36 months at the time of booster administration, respectively. 
 
Immunogenicity assessments 
Blood samples were obtained by venipuncture and centrifuged at 1500 g for 10 minutes; sera were 
stored at a temperature of -18C or below and shipped to the Novartis Vaccines Clinical Serology 
Laboratory in Marburg, Germany, where antibody responses were assessed by haemagglutination 
(HI) and microneutralization (MN) assays. The HI assay was based on the method of Stephenson 
and colleagues;
12
 HI titre was expressed as the reciprocal of the highest dilution at which 
haemagglutination was totally inhibited. MN assays were performed according to a method 
previously described by Nicholson and colleagues, serial dilutions of serum started at 1:20; the 
reciprocals of two-fold dilutions that achieved ≥ 50% neutralization of viral growth were considered 
a positive result.
13
 Titers were reported in terms of Geometric Mean Titers (GMT). Geometric Mean 
Ration (GMR) were calculated as GMT Day 22/GMT Day 1, GMT Day 43/GMT Day 1, GMT Day 
366/GMT Day 1 and GMT Day 387/GMT Day 366. In addition, HI GMT titers greater or equal 
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than 1: 40 were assessed. Seroconversion, as assessed by HI assay, was defined as a negative pre-
vaccination antibody titre of < 1:10 to a positive post-vaccination titre of ≥ 1:40, or a minimum 
four-fold increase where pre-vaccination titres were ≥ 1:10. HI titres below the detection limit of 
1:10 were arbitrarily assigned to half that limit (1:5) for the purpose of analysis. The HI titer of 
1:40, which has been determined as an immunologic correlate corresponding to a 50% reduction in 
the risk of contracting influenza, is based on studies in adults and may not be generalizable to 
children. Indeed, a recent study in a large pediatric population indicated that the conventional HI 
titer of 1:40 was only associated with 22% protection.
14
 Therefore, percentages of subjects with HI 
titers ≥ 1:330 were also calculated, as this cut-off titer has been shown to predict an 80% clinical 
protective level in young children. Homologous HI and MN assays were performed using the 
vaccine antigen strain A/California/7/2009 (H1N1). 
 
Safety assessment 
Subjects were observed for 30 minutes after receipt of each vaccine dose to monitor for immediate 
adverse reactions. The frequency and severity of solicited local and systemic reactions occurring 
within one week of each vaccination were recorded on diary cards and summarized according to the 
Brighton collaboration case definition.
15
 Solicited local reactions were ecchymosis, erythema, 
induration, swelling, (graded as mild, moderate, severe based on measurement in mm) and 
tenderness. Solicited systemic reactions were sleepiness, diarrhoea, vomiting, irritability, altered 
eating habits, shivering, unusual crying, and fever (≥ 38C). A high, grade 3 fever was defined as an 
axillary body temperature of ≥ 40C. Solicited systemic reactions were collected as present/not 
present. In addition, use of analgesic/antipyretic was collected as measure of reactogenicity. All 
unsolicited adverse events (AE) were recorded for three weeks after each vaccination. The onset of 
new chronic diseases, serious adverse events (SAEs), and AEs leading to withdrawal were recorded 
throughout the entire study period (Day 1–546). A physician rated AEs as mild, moderate, or severe 
if resulting in no limitation of, some limitation of, or inability to perform normal daily activities, 
respectively. 
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Statistical analyses 
Sample sizes were chosen to meet or exceed the minimum requirements of the European guidelines 
for influenza vaccine clinical trials. No formal statistical hypothesis was tested, immunogenicity 
endpoints being based on HI licensure criteria established by the EU Committee for Medicinal 
Products for Human Use (CHMP).
16
 There are currently no pre-defined CHMP criteria for children, 
therefore, the following adult licensure criteria applied: the number of subjects achieving 
seroconversion or significant increase (defined as HI ≥ 1:40 for subjects with a pre-vaccination HI 
titer <1:10; a minimum 4-fold increase HI titer for subjects with a pre-vaccination HI titer ≥1:10) 
should be > 40%; geometric mean ratios (GMRs) should be > 2.5; and the proportion of subjects 
achieving an HI titre ≥ 1:40 should be > 70%. Percentages of subjects with HI titers ≥ 1:330 were 
also calculated.
14
 Immunogenicity data reflecting the above endpoints as well as the corresponding 
two-sided 95% confidence intervals (CIs) were calculated for each vaccine group and age cohort 
using two-way analysis of variance (ANOVA) with factors for vaccine group and center. Safety 
data were evaluated descriptively and expressed as the proportion and number of subjects with AEs 
in each group. Immunogenicity analyses were run on the per-protocol (PP) set, which consisted of 
subjects who received all the relevant doses of vaccine correctly, provided evaluable serum sample 
at the relevant time points, and had no major protocol violations. Safety was analyzed for all 
subjects exposed to at least one study vaccination and provided safety data. All statistical analyses 
were performed by employees of Novartis Vaccines and Diagnostics using SAS 9.1
®
 software. 
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Results 
After the removal of one study site, 330 subjects were included in the two age cohorts (6-11 months 
and 12-35 months) covered in this paper.  In this study, 64-78% across groups completed the study 
protocol (Figure 1). An average of 93% and 72% of subjects across study groups completed the 
primary immunization schedule (Day 43) and received the booster dose (Day 366), respectively. A 
second dose of seasonal vaccine at Day 387 was administered to about 47% of subjects across 
vaccine groups in both age cohorts. 
Demographic and other baseline population characteristics are shown in Table 1. The majority of 
children were of Hispanic ethnic origin. Mean age of the subjects was 8.5 months and 24.2 months 
in cohorts 6-11 months and 12-35 months, respectively 
 
Immunogenicity 
Immunogenicity analyses were performed on the PP data set, which included 68-76% of subjects 
across groups after the primary vaccination schedule (Day 43), 49-53% of subjects for persistence 
analyses (Day 366), and 32-55% of subjects for post-booster analyses (Day 387).   
HI assay GMTs were low at baseline, with only 18–26% of subjects displaying HI titres of ≥ 1:40 
(Table 2). In the 6–11 months cohort, 7.5-Full MF59 vaccine induced greater GMTs than the 3.75-
Half MF59 formulation three weeks after both first and second doses (Figure 2A). One dose of 
either MF59-adjuvanted vaccine was sufficient to meet the CHMP criterion for GMR (Table 2). In 
the 12–35 months cohort, the 7.5-Full MF59 vaccine induced greater GMTs than the 3.75-Half 
MF59 formulation after first and second doses (Figure 2B). GMTs were greater in response to both 
MF59-adjuvanted vaccines compared with the 15 g non-adjuvanted formulation (Figure 2B). All 
three vaccine formulations met the licensure criterion for GMRs as early as 3 weeks after the first 
vaccination (Table 2). Subjects in the 6–11 months cohort demonstrated high HI seroconversion 
rates for both formulations after the first and second vaccinations (91–98%); the same was true in 
subjects in the 12–35 months cohort who received adjuvanted formulations (97–100%; Table 2). 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
9 
 
Seroconversion rates were lower in subjects who received the 15-No MF59 formulation (52% on 
Day 22 and 74% on Day 43) than those who received adjuvanted formulations. For both age 
cohorts, seroconversion rates for all vaccines were above the CHMP licensure criterion of > 40% 
after both the first and second vaccinations. Rates of subjects with HI titers ≥ 1:40 were high after 
first and second doses in response to both adjuvanted formulations in both age cohorts, ranging 
from 91% to 100% (Figure 3A and B), exceeding the CHMP criterion of > 70%. Rates of subjects 
with HI titers ≥ 1:40 in the 15-No MF59 vaccination group of the 12–35 months cohort failed to 
meet licensure criterion after the first dose (52%); a second dose was required for this criterion to be 
achieved (81%) (Figure 3B). Analyses by MN assay supported HI data (Figure 2C and D, Table 
3). 
Long-term antibody persistence was demonstrated in subjects receiving MF59-adjuvanted vaccines; 
95–100% of subjects across age groups achieved HI titers ≥ 1:40 one year after immunization, 
which is considerably higher than in those receiving the non-adjuvanted formulation (62%) (Figure  
3A and B). Antibody titres were significantly higher after booster vaccination compared with 
GMTs after priming doses (Figure 2). The licensure criteria for GMR and seroconversion were met 
by all priming groups following booster vaccination in both age cohorts (Table 2) and all subjects 
achieved HI titers ≥ 1:40 in all vaccine groups in both age cohorts, regardless of priming 
formulations.. Analyses by MN assay supported HI data (Figure 2C and D, Table 3). 
Percentages of subjects with HI titers ≥ 1:330 are reported in Table 4. In the 6–11 months cohort, 
35% (3.75-Half MF59), 39% (7.5-Full MF59) and 82% (3.75-Half MF59), 100% (7.5-Full MF59) 
of subjects achieved HI titers ≥ 1:330 after the first and second primary doses, respectively, and all 
subjects in both vaccine groups had HI titers ≥ 1:330 after the booster vaccination.  
In children 12-35 months of age receiving adjuvanted formulations, percentages of subjects 
achieving HI titers ≥ 1:330 were higher compared with subjects receiving the nonadjuvanted 
formulation. HI titers ≥ 1:330 were achieved in 37% (3.75-Half MF59), 47% (7.5 Full MF59), 23% 
(15-No MF59), and 85% (3.75-Half MF59), 91% (7.5-Full MF59), 39% (15-No MF59) after the 
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first and second primary doses, respectively and in 100% (both adjuvanted formulations) and 91% 
(15-No MF59) of subjects after the booster dose.  
Safety and tolerability 
All subjects were exposed to at least one study vaccination and contributed to the safety analyses. 
In the 6–11 months cohort, the percentage of subjects with solicited local reactions were similar 
between first and second primary doses, and between the two adjuvanted formulations (Table 5).  
The most frequently reported local reactions after primary immunizations were erythema (15–25% 
of subjects) and tenderness (14–25%). There were no cases of severe local reactions after primary 
vaccinations. Local reactions were generally more frequent after the booster dose than the primary 
doses. Tenderness was the most frequently reported local reaction after the booster (34–39%) and 
second (23–30%) seasonal dose, followed by erythema (28–31% and 22–30%, respectively). Severe 
reactions were reported in up to 8% and 6% across groups after booster dose and second seasonal 
dose, respectively, with tenderness as the most frequently reported severe local reaction. The 
incidence of solicited systemic reactions was generally lower after the second primary vaccination 
compared with the first primary vaccination in the 6–11 months cohort, no substantial differences 
were observed between the vaccine groups. The incidence of systemic reactions after the booster 
was similar to that after the second primary vaccination. The incidence of local and systemic 
reactions tended to be lower after the second seasonal vaccination compared to the booster (Table 
5).  
In the 12–35 months cohort (Table 6), solicited local reactions were less frequent in the non-
adjuvanted formulation compared with the adjuvanted formulations and occurred at a similar rate 
after the first and second primary doses. 
Tenderness was the most frequently reported local reaction after the primary immunizations (22–
35%), increasing in frequency after the booster (34–48%), but decreasing in frequency after the 
second seasonal dose (15–29%). Other local reactions occurred at a similar rate after the primary 
and booster vaccinations, but tended to occur at a lower rate after the second seasonal vaccination. 
After primary immunizations, severe tenderness was reported in 1-3% of subjects across adjuvanted 
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groups, and severe induration and erythema occurred in 1% of subjects receiving 7.5-full MF59. 
Following booster and second seasonal dose, severe tenderness was reported in up to 5% of subjects 
across adjuvanted formulations. Systemic reactions tended to be similar between the vaccine 
formulations after the primary immunizations in the 12–35 months cohort.  
There were three reports of fever ≥ 40C: one in the 6-11 months cohort (3.75-Half MF59) and two 
in the 12-35 months cohort (n=1: 3.75-Half MF59, n=1: 7.5-Full MF59), all following the first 
vaccination. Cases occurred between 3-5 days postvaccination and all resolved within 1-2 days 
without sequelae.  
 
For spontaneously reported AEs, no differences in overall frequency of AEs were observed between 
the two adjuvanted formulations and between adjuvanted and nonadjuvanted vaccine groups.   
Between study Days 1 and 43, AEs were spontaneously reported for 51–60% of subjects across age 
and vaccine groups; 5–16% of these cases were considered at least possibly related to vaccination. 
In the 6-11 months cohort, the most commonly reported AEs were nasopharyngitis (23–31%), 
followed by diarrhea (12-13%); in the 12-35 months cohort, the most commonly reported AEs were 
nasopharyngitis (25-30%) and bronchitis (7-16%).  
Selected unsolicited AEs from Day 1-Day 546 are presented in Table 7. Between Days 1-366, there 
were 25 subjects with SAEs and 8 subjects with new onset chronic diseases. None of these SAEs 
and new onset of chronic diseases was considered as related to study vaccination. There were 3 AEs 
leading to premature study withdrawal, one AE was considered at least possibly related to study 
vaccination (6-11 months cohort, 3.75-Half MF59 group; subject experienced mild allergic 
dermatitis on day 2, the AE resolved in 6 days).  
After the booster vaccination, the most frequently reported unsolicited AEs were nasopharyngitis 
(12–13%), and diarrhoea (2–6%) in the 6–11 months cohort, and nasopharyngitis (6–9%) and 
conjunctivitis (0–5%) in the 12-15 months cohort. Nasopharyngitis was also the most frequently 
reported AE after the second dose of the seasonal MF59 vaccine in both the 6–11 months (15%) 
and 12–35 months (12%) cohorts.  
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One 6–11 month-old subject in the 3.75-Half MF59 group experienced one SAE, and one 12–35 
month-old subject in the 3.75-Half MF59 group experienced two SAEs between booster 
administration and the end of the study (Day 366–546). No SAEs were related to either the booster 
or the second seasonal vaccination. There was one new onset of chronic disease in 6-11 month 
(asthmatic crisis) and 12-35 month (allergic rhinitis) age cohorts, and one AE leading to premature 
study withdrawal in a 6-11 month-old subject (food allergy), none of which related to study 
vaccination between booster administration and the end of the study.   
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Discussion 
 
All the investigational vaccines used in this study were shown to be highly immunogenic and well 
tolerated in children from 6 to 35 months of age. Both MF59-adjuvanted formulations induced 
higher antibody responses compared with the non-adjuvanted vaccine. A single dose of either the 
3.75-Half MF59 or 7.5-Full MF59 vaccines was sufficient to meet all three European licensure 
criteria for influenza vaccines; two doses of the non-adjuvanted vaccine were required to achieve 
similar results. The ability of MF59 to allow for reduced antigen content would potentially ensure a 
higher coverage during a pandemic outbreak, which is an important public health issue to consider 
in periods of heightened demand. 
The findings of this study are supported by similar trials. A cell culture-derived, MF59-adjuvanted 
A/H1N1 vaccine has been demonstrated to provide adequate levels of antibodies after a single dose 
in British adults 
6
 and Japanese adults and children.
17, 18
 Adults were found to require one 3.75-Half 
MF59 vaccine dose, while a single 7.5-Full MF59 dose was optimal for children in the Japanese 
study.
18
 A trial of A/H1N1 vaccine was conducted in Costa Rican children to compare an MF59-
adjuvanted formulation containing 7.5 g of A/California/7/2009 antigen with 15 g and 30 g 
non-adjuvanted vaccines.
4
 All three vaccines met the US Center for Biologics Evaluation and 
Research (CBER) and CHMP licensure criteria after one dose in subjects aged 9–17 years; only the 
MF59-adjuvanted formulation met these criteria after one dose in younger subjects of 3 to 8 years. 
Paediatric and adult clinical trials using an AS03
®
-adjuvanted (GlaxoSmithKline Biologicals, 
Wavre, Belgium) A/H1N1 vaccine have also demonstrated that a single dose containing 3.75 g 
antigen is sufficient in combination with an oil-in-water adjuvant.
19, 20
 
It has recently been demonstrated that the conventional titer of 1:40 correlate may not be 
appropriate in a pediatric population.
14
 A titer of 1:40 was only associated with 22% protection, 
whereas titers of 1:110 or 1:330 could predict a 50% or an 80% of clinical protective level.
14
 Our 
results demonstrate that in children receiving MF59 adjuvanted formulations, a high proportion 
reached the stringent HI cut-off titer ≥ 1:330 postvaccination, i.e. 82-100% and 100% after primary 
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and booster doses respectively, as compared with 39% in children receiving the non-adjuvanted 
vaccine. The seasonal MF59 vaccine was able to boost the immune responses also in the group 
primed with the nonadjuvanted formulation: indeed, 91% of subjects primed with the non-
adjuvanted vaccine reached the HI cut-off titer ≥ 1:330.  These findings give strong support for the 
use of MF59 adjuvanted vaccines in the pediatric population.  
In the present study, significant antibody persistence was observed in response to the MF59-
adjuvated vaccine formulations, with HI titers ≥ 1:40 detected in 95–100% of subjects one year 
after immunization. The ability of MF59 to promote long-term antibody persistence has also been 
demonstrated in previous studies.
21, 22
 All subjects in the current study received two priming doses; 
as such, further investigations are required to confirm that long-term antibody persistence and 
response to booster vaccination is not negatively affected by a one-dose priming schedule. The 
production of cross-reactive antibodies able to provide heterologous immunity was not analysed 
during this study. However, the ability of MF59 to promote the production of cross-reactive 
antibodies is well documented.
21, 23-25 
The overall safety and tolerability were as expected in this age group and were in line with previous 
studies using MF59-adjuvanted vaccines in young children.
18, 26-28
 Solicited local reactions were 
more common in adjuvanted formulations compared with nonadjuvanted vaccine, but there were no 
MF59-related increase in the frequency of solicited systemic reactions or unsolicited adverse 
events. This study demonstrated an acceptable safety profile for the adjuvanted vaccine over an 18-
month period; although subjects were repeatedly vaccinated with up to four doses of MF59-
adjuvanted vaccine, no vaccine-related SAEs were reported during the study period. 
In conclusion, a single dose of 3.75μg antigen together with half the standard dose of MF59 was 
identified as optimal, provided adequate levels of immediate and long-term antibodies and an 
acceptable safety profile in children 6-35 months of age. These data support the suitability of 
Focetria for pandemic immunization in the paediatric population. 
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Figure legends 
 
Figure 1: Design of clinical trial and subject disposition. 
 
Figure 2: GMTs by HI (A and B) and MN (C and D) assay at baseline (Day 1), three weeks after 
first (Day 22) and second (Day 43) priming doses, and pre- and post-booster vaccination in children 
aged 6–11 months- (A and C) and 12–35 months old (B and D). 
 
Figure 3: Percentages (95% CI) of subjects aged 6–11 months (A) and 12–35 months (B) achieving 
HI titer ≥ 1:40 after primary and booster immunizations. Broken line represents the CHMP 
licensure criteria. 
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Table 1: Study population demographics  
 
 
  6–11 Months  12–35 Months 
  
3.75-Half MF59 
(n = 72) 
7.5-Full MF59 
(n = 72) 
 
3.75-Half MF59 
(n = 75) 
7.5-Full MF59 
(n = 74) 
15-No MF59 
(n = 37) 
Age (months, SD)  8.8 ± 1.3 8.3 ± 1.4  24.0 ± 7.4 23.9 ± 6.4 25.1 ± 6.4 
Male (%)  50 49  53 57 46 
Asian (%)  3 0  5 5 5 
Black (%)  3 0  1 3 3 
Caucasian (%)  14 18  28 30 32 
Hispanic (%)  76 79  56 54 54 
Other (%)  4 3  9 8 5 
Weight (kg, SD)  9 ± 1.2 8.9 ± 1.2  12.3 ± 2.3 12.6 ± 1.9 12.9 ± 2.1 
Height (cm, SD)  71.7 ± 3.7 70.6 ± 3.6  86.0 ± 7.2 87.4 ± 5.8 88.5 ± 6.7 
Body Mass Index (kg/m
2
, SD)  17.5 ± 1.9 17.8 ± 2.0  16.7 ± 2.1 16.5 ± 1.6 16.6 ± 2.0 
Previous influenza vaccination (%)  0 1  44 41 51 
                                  SD: standard deviation 
Table 1
Table 2: HI assay: immunogenicity analysis (95% CI) against A/H1N1/California/7/2009, at baseline (Day 1), three weeks after first (Day 22) 
and second (Day 43) primary doses, one year after vaccination (Day 366) and three weeks after booster vaccination (Day 387). Bold: CHMP 
criterion met 
  6–11 Months  12–35 Months 
  
3.75-Half MF59 
(n prime = 55) 
 (n MF59-TIV boost = 26) 
7.5-Full MF59 
(n prime = 49) 
 (n MF59-TIV boost = 30) 
 
 
 
3.75-Half MF59 
(n prime = 60) 
 (n MF59-TIV boost = 44) 
7.5-Full MF59 
(n prime = 58) 
 (n MF59-TIV boost = 42) 
15-No MF59 
(n prime = 31) 
 (n MF59-TIV boost = 23) 
Baseline values 
GMTs  12 (6.9–22) 15 (8.0–27)  7.7 (4.0–15) 10 (5.2–20) 12 (6.2–24) 
% subjects HI titer ≥ 40  22 (12–35) 22 (12–37)  18 (10–30) 24 (14–37) 26 (12–45) 
GMRs 
Day 22 : 1 (1
st
 dose)  15 (9.8–22) 21 (14–33)  28 (17–44) 31 (19–51) 4.6 (2.8–7.5) 
Day 43 : 1 (2
nd
 dose)  79 (44–142) 121 (66–225)  91 (51–162) 80 (44–146) 12 (6.4–21) 
Day 366 : 1 (pre-booster)  
23 (14–39) 
 (n=38) 
32 (19–55) 
 (n=35) 
 
39 (20–75) 
 (n=46) 
25 (13–48) 
 (n=51) 
3.4 (1.7–6.7)  
(n=26) 
Day 387 : 366 (post-
booster) 
 14 (8.4–24) 8.1 (5.0–13)  12 (5.8–24) 9.1 (4.5–19) 31 (15–64) 
% of subjects achieving seroconversion  
Day 22 (1
st
 dose)  91 (80–97) 96 (86–100)  97 (88–100) 100 (94–100) 52 (33–70) 
Day 43 (2
nd
 dose)  96 (87–100) 98 (89–100)  100 (94–100) 100 (94–100) 74 (55–88) 
Day 387 (post-booster) 
(from Day 366) 
 81 (61–93) 77 (58–90)  80 (65–90) 86 (71–95) 78 (56–93) 
HI: haemagglutinination inhibition; GMT: geometric mean titer; GMR: geometric mean ratio 
Table 2
Table 3: MN assay: immunogenicity analysis (95% CI) against A/H1N1/California/7/2009, at baseline (Day 1), three weeks after first (Day 22) 
and second (Day 43) primary doses, one year after vaccination (day 366) and three weeks after booster vaccination (Day 387) 
 
  6–11 Months  12–35 Months 
  
3.75-Half MF59 
(n prime = 55) 
(n MF59-TIV boost = 26) 
7.5-Full MF59 
(n prime = 49) 
(n MF59-TIV boost = 30) 
 
 
 
3.75-Half MF59 
(n prime = 60) 
(n MF59-TIV boost = 44) 
7.5-Full MF59 
(n prime = 58) 
(n MF59-TIV boost = 42) 
15-No MF59 
(n prime = 31) 
(n MF59-TIV boost = 22) 
Baseline values 
GMTs  12 (6.2–24) 14 (6.8–29)  7.7 (3.5–17) 10 (4.5–22) 11 (5.1–26) 
% of subjects MN titer ≥ 1:40  22 (12–35) 22 (12–37)  18 (10–30) 24 (14–37) 23 (10–41) 
GMRs 
Day 22 : 1 (1
st
 dose)  28 (17–45) 36 (22–59)  36 (22–59) 36 (22–60) 4.7 (2.8–7.9) 
Day 43 : 1 (2
nd
 dose)  144 (81–256) 208 (113–383)  226 (120–427) 202 (104–391) 34 (18–66) 
Day 366 : 1 (pre-booster)    
29 (15–54)  
(n=38) 
32 (17–62)  
(n=35) 
 
34 (17–66)  
(n=46) 
21 (11–40)  
(n=51) 
5.1 (2.5–10)  
(n=25) 
Day 387 : 366 (post-booster)  12 (8.3–18) 9.2 (6.5–13)  18 (10–31) 14 (8.3–25) 21 (11–38) 
% of subjects MN titer ≥ 1:40 
Day 22 (1
st
 dose)  95 (85–99) 100 (93–100)  100 (94–100) 100 (94–100) 52 (33–70) 
Day 43 (2
nd
 dose)  100 (94–100) 100 (93–100)  100 (94–100) 100 (94–100) 94 (79–99) 
Day 387 (post-booster)  100 (87–100) 100 (88–100)  100 (92–100) 100 (92–100) 100 (85–100) 
MN: microneutralization; GMT: geometric mean titer; GMR: geometric mean ratio 
Table 3
Table 4: Percentages of Subjects (95% CI) With HI Titer ≥ 1:330 against the vaccine strain A/H1N1/California/7/2009 at baseline (Day 1), three 
weeks after first (Day 22) and second (Day 43) primary doses, one year after vaccination (Day 366), and three weeks after booster vaccination 
(Day 387)  
 
 
  6–11 Months  12–35 Months 
  
3.75-Half MF59 
(n prime = 55) 
(n MF59-TIV boost = 26) 
7.5-Full MF59 
(n prime = 49) 
(n MF59-TIV boost = 30) 
 
 
 
3.75-Half MF59 
(n prime = 60) 
(n MF59-TIV boost = 44) 
7.5-Full MF59 
(n prime = 58) 
(n MF59-TIV boost = 42) 
15-No MF59 
(n prime = 31) 
(n MF59-TIV boost = 23) 
% of subjects with HI titers ≥ 1:330 
Day 1 Baseline  4 (0-13) 8 (2-20)  2 (0.04–9) 0 (0-6) 6 (1-21) 
Day 22 (1
st
 dose)  35 (22-49) 39 (25-54)  37 (25-50) 47 (33-60) 23 (10-41) 
Day 43 (2
nd
 dose)  82 (69–91) 100 (93–100)  85 (73-93) 91 (81-97) 39 (22-58) 
Day 366 (pre-booster)  
42 (26–59) 
 (n=38) 
71 (54–85) 
 (n=35) 
 
50 (35–65)  
(n=46) 
57 (42–71)  
(n=51) 
27 (12–48)  
(n=26) 
Day 387 (post-booster)  100 (87-100) 100 (88-100)  100 (92-100) 100 (92-100) 91 (72-99) 
HI: haemagglutinination inhibition 
Table 4
Table 5: 6–11 months cohort: percentages of subjects experiencing solicited local* and systemic reactions within one week of each vaccination. 
Percentages of subjects with reactions classified as severe are shown in brackets 
 
Solicited systemic reactions were collected as present/not present
  
a
Tenderness was classified as severe if subjects cried on movement of limb. 
b
Fever was classified as severe if ≥ 40C. Body temperatures were converted into axillary 
measured temperatures by subtracting 1.0C from rectally, 0.5C from orally and 0.2C from tympanically measured body temperature 
 First Dose Second Dose MF59-TIV (Booster) MF59-TIV (2
nd
 Seasonal Dose) 
 
3.75-Half MF59 
(n = 72) 
7.5-Full MF59 
(n = 73) 
3.75-Half MF59 
(n = 69) 
7.5-Full MF59 
(n = 68) 
3.75-Half MF59 
(n = 50) 
7.5-Full MF59 
(n = 49) 
3.75-Half MF59 
(n = 46) 
7.5-Full MF59 
(n = 47) 
Ecchymosis* 4 (0) 3 (0) 4 (0) 3 (0) 8 (0) 8 (0) 0 (0) 2 (2) 
Erythema* 21 (0) 25 (0) 19 (0) 15 (0) 28 (0) 31 (2) 22 (0) 30 (4) 
Induration* 4 (0) 3 (0) 7 (0) 6 (0) 18 (0) 24 (2) 13 (0) 19 (2) 
Swelling* 3 (0) 1 (0) 3 (0) 3 (0) 12 (0) 16 (2) 11 (0) 11 (2) 
a
Tenderness* 15 (0) 25 (0) 14 (0) 16 (0) 34 (8) 39 (4) 30 (2) 23 (6) 
Sleepiness 42 47 25 34 16 27 13 4 
Diarrhoea 29 32 20 18 18 16 7 6 
Vomiting 14 15 14 7 6 12 4 4 
Irritability 31 27 17 31 28 35 13 11 
Altered eating habits 25 27 14 18 20 27 4 6 
Shivering 8 7 4 1 8 8 2 4 
Crying 36 33 19 26 32 27 15 17 
b
Fever ≥38°C 13 (1) 14 (0) 7 (0) 13 (0) 24 (0) 22 (0) 9 (0) 17 (0) 
Use of 
analgesic/antipyretic 
31 32 19 29 30 41 20 19 
Table 5
Table 6: 12–35 months cohort: percentages of subjects experiencing solicited local* and systemic reactions within one week of each vaccination. 
Percentages of subjects with reactions classified as severe are shown in brackets 
Solicited systemic reactions were collected as present/not present
  
a
Tenderness was classified as severe if subjects cried on movement of limb. 
b
Fever was classified as severe if ≥ 40C. Body temperatures were converted into axillary 
measured temperatures by subtracting 1.0C from rectally, 0.5C from orally and 0.2C from tympanically measured body temperature 
 First Dose Second Dose MF59-TIV (Booster) MF59-TIV (2
nd
 Seasonal Dose) 
 
3.75- 
Half MF59 
(n = 75) 
7.5- 
Full MF59 
(n = 73) 
15- 
No MF59 
(n = 37) 
3.75- 
Half MF59 
(n = 73 
7.5- 
Full MF59 
(n = 72) 
15- 
No MF59 
(n = 36) 
3.75- 
Half MF59 
(n = 52) 
7.5- 
Full MF59 
(n = 57) 
15- 
No MF59 
(n = 29) 
3.75- 
Half MF59 
(n = 24) 
7.5- 
Full MF59 
(n = 27) 
15- 
No MF59 
(n = 13) 
Ecchymosis* 11 (0) 10 (0) 5 (0) 7 (0) 13 (0) 11 (0) 10 (0) 9 (0) 3 (0) 8 (0) 7 (0) 0 (0) 
Erythema* 28 (0) 25 (0) 19 (0) 18 (0) 25 (1) 22 (0) 38 (0) 28 (0) 10 (0) 25 (0) 22 (0) 8 (0) 
Induration* 5 (0) 11 (0) 5 (0) 11 (0) 10 (1) 3 (0) 31 (0) 18 (0) 7 (0) 25 (0) 7 (0) 0 (0) 
Swelling* 4 (0) 3 (0) 3 (0) 5 (0) 3 (0) 3 (0) 23 (0) 12 (0) 7 (0) 17 (0) 4 (0) 0 (0) 
a
Tenderness* 35 (3) 34 (3) 22 (0) 25 (1) 33 (1) 28 (0) 48 (2) 40 (5) 34 (0) 29 (4) 15 (4) 23 (0) 
Sleepiness 39 29 30 23 18 33 13 9 14 8 4 8 
Diarrhoea 24 21 24 14 17 14 8 9 7 17 7 8 
Vomiting 9 5 11 10 10 11 4 11 3 4 0 0 
Irritability 28 29 27 26 22 31 25 21 17 13 7 8 
Altered eating 
habits 
24 19 16 22 15 22 10 5 14 17 7 8 
Shivering 11 10 11 10 3 8 4 7 7 0 0 8 
Crying 31 29 24 18 19 22 21 18 17 13 15 8 
b
Fever ≥ 38°C 9 (1) 15 (1) 8 (0) 11 (0) 14 (0) 0 (0) 12 (0) 19 (0) 7 (0) 8 (0) 0 (0) 0 (0) 
Use of 
analgesic/antipyretic 
15 19 22 21 21 17 25 25 14 4 4 0 
Table 6
Table 7. Number and percentages of subjects with selected unsolicited adverse events, Days 1-546  
  6–11 Months  12–35 Months 
  
3.75-Half MF59 
(n = 72) 
7.5-Full MF59 
(n = 72) 
 
3.75-Half MF59 
(n = 75) 
7.5-Full MF59 
(n = 74) 
15-No MF59 
(n = 37) 
Day 1-366        
Serious AEs  8 (11%) 6 (8%)  6 (8%) 3 (4%) 2 (5%) 
At least possibly related SAEs  0 0  0 0 0 
AEs leading to discontinuation  2 (3%) 0  1 (1%) 0 0 
At least possibly related AEs 
leading to discontinuation 
 1 (1%) 0  0 0 0 
New onset of chronic diseases  5 (7%) 1 (1%)  0 1 (1%) 1 (3%) 
At least possibly related new onset 
of chronic diseases 
 0 0  0 0 0 
Day 366-546  
3.75-Half MF59 
(n = 68) 
7.5-Full MF59 
(n = 62) 
 
3.75-Half MF59 
(n = 63) 
7.5-Full MF59 
(n = 68) 
15-No MF59 
(n = 35) 
Serious AEs  1 (1%) 0  1 (2%) 0 0 
At least possibly related SAEs  0 0  0 0 0 
AEs leading to discontinuation  0 1 (2%)  0 0 0 
At least possibly related AEs 
leading to discontinuation 
 0 0  0 0 0 
New onset of chronic diseases  1 (1%) 0  1 (2%) 0 0 
At least possibly related new onset 
of chronic diseases 
 0 0  0 0 0 
 
Table 7
Completed Protocol  
Day 1: Baseline immunogenicity analyses and vaccine dose 1 
Day 22: Post-dose 2 immunogenicity analyses and vaccine dose 2 
Day 43: Post-dose 2 immunogenicity analyses  
Day 366: Immunogenicity analyses (persistence) and booster dose 1  
Day 387*: Post-booster dose analyses, and if applicable, a second dose of seasonal MF59-TIV* 
3.75-Half MF59 
n=47 (65%) 
 
Adverse event (n=2) 
Withdrawal consent (n=4) 
Lost to follow up (n=2) 
Administration (n=6) 
Unable to classify (n=11) 
 
 
 
3.75-Half MF59 
(n=72) 
 
 
 
 
7.5-Full MF59 
(n=72) 
 
 
 
 
3.75-Half MF59 
(n=75) 
 
 
 
 
7.5-Full  MF59 
(n=74) 
 
 
 
 
15-No MF59 
(n=37) 
 
 
Enrolled and randomized: N=368 
One site was excluded from analyses (n=21: 12-35 months; n=17: 6-11 months) 
 
Number of subjects analyzed: N=330 
 
 
6-11 months  
(n=144) 
 
 
 
 
12-35 months  
(n=186) 
  
 
7.5-Full MF59 
n=46 (64%) 
 
Adverse event (n=1) 
Withdrawal consent (n=11) 
Lost to follow up (n=1) 
Administration (n=5) 
Protocol deviation (n=1) 
Unable to classify (n=7) 
3.75-Half MF59 
n=52 (69%) 
 
Adverse event (n=1) 
Withdrawal consent (n=10) 
Lost to follow up (n=8) 
Administration (n=3) 
Unable to classify (n=1) 
7.5-Full MF59 
n=58 (78%) 
 
Withdrawal consent (n=10) 
Lost to follow up (n=4) 
Administration (n=2) 
 
 
15-No MF59 
n=28 (76%) 
 
Withdrawal consent (n=2) 
Lost to follow up (n=3) 
Administration (n=1) 
Unable to classify (n=3) 
 
One German site was excluded from analyses due to to noncompliance with the protocol requirements for safety reporting for a different study  
*subjects who had never previously received seasonal vaccine were given a second dose of seasonal MF59-TIV at Day 387 to complete the seasonal 
immunization course according to WHO recommendations; the immunogenicity of this second seasonal immunization was not investigated.  
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